T
Taiga Otsuka
Researcher at Saga University
Publications - 3
Citations - 50
Taiga Otsuka is an academic researcher from Saga University. The author has contributed to research in topics: Sorafenib & Gemcitabine. The author has an hindex of 3, co-authored 3 publications receiving 35 citations.
Papers
More filters
Journal ArticleDOI
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
Satoshi Kobayashi,Takeshi Terashima,Satoshi Shiba,Yukio Yoshida,Ikuhiro Yamada,Shouta Iwadou,Shigeru Horiguchi,Hideaki Takahashi,Eiichiro Suzuki,Michihisa Moriguchi,Kunihiro Tsuji,Taiga Otsuka,Akinori Asagi,Yasushi Kojima,Ryoji Takada,Chigusa Morizane,Nobumasa Mizuno,Masafumi Ikeda,Makoto Ueno,Junji Furuse +19 more
TL;DR: The platinum‐containing regimens such as gemcitabine/cisplatin were associated with more favorable outcomes than sorafenib monotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Journal ArticleDOI
Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
Taiga Otsuka,Chigusa Morizane,Satoshi Nara,Hideki Ueno,Shunsuke Kondo,Kazuaki Shimada,Tomoo Kosuge,Masafumi Ikeda,Nobuyoshi Hiraoka,Takuji Okusaka +9 more
TL;DR: Among patients who had IPMN-IC and IDC with recurrent disease after resection, there was no significant difference in treatment outcomes after gemcitabine.
Journal ArticleDOI
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
Takuji Okusaka,Taiga Otsuka,Hideki Ueno,Shuichi Mitsunaga,Rie Sugimoto,Kei Muro,Isao Saito,Yusuke Tadayasu,Kohei Inoue,Arsene-Bienvenu Loembe,Masafumi Ikeda +10 more
TL;DR: Nintedanib showed a manageable safety profile and efficacy signals, including in patients previously treated with sorafenib, in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment.